PONY(SZ:300887)2025-05-08 10:06Financial Performance - In 2024, the company achieved a revenue of CNY 154,139.97 million, with a net profit attributable to shareholders of CNY -35,631.30 million, primarily due to strategic contraction and customer structure optimization in a complex market environment [2] - In Q1 2025, the company reported a revenue of CNY 25,172.11 million, with a net profit of CNY -11,096.75 million, attributed to the seasonal nature of the business [3] Strategic Measures - The company implemented strategic contraction by reducing less profitable business segments such as construction materials and non-destructive testing, while integrating food, environment, and medical laboratory capacities [4] - Strengthened accounts receivable management and optimized customer structure, conducting impairment tests on long-term assets showing signs of impairment [4] Business Development - In 2024, the Shanghai biopharmaceutical division received the GLP certification from the NMPA, enhancing the group's drug innovation and research capabilities [5] - The Suzhou automotive laboratory improved testing capabilities for automotive seats and expanded its testing capacity for airbags and other components, gaining recognition from major automotive manufacturers [6][7] Future Plans - The company plans to cautiously reduce capital expenditures while optimizing internal resource allocation and improving capacity utilization [7] - Future strategies include deepening customer demand exploration in sectors like biopharmaceuticals, medical devices, and new energy vehicles, while maintaining strict operational budgets [7]